Foundation Medicine, Roche and DIAN Diagnostics Collaborate to Advance Personalized Cancer Care in China
--DIAN Designated Roche’s and Foundation Medicine’s Exclusive Clinical Sequencing Partner in
--
- DIAN, a leader in the development and supply of Chinese medical diagnostic products and services, becomes the exclusive clinical sequencing partner in
China for FoundationOne®, FoundationACT® and FoundationOne®Heme, enabling the delivery of personalized cancer care for patients. Roche maintains commercial exclusivity for Foundation Medicine’s molecular information products inChina , and in cooperation with DIAN continues its current in-county activities to support the broad integration of CGP into clinical care.
Cancer is the leading cause of death among China's population of 1.4 billion. In 2015, there were approximately 4.3 million new cancer cases and more than 2.8 million cancer deaths in China1. Given the high volume of new and emerging oncology research, new innovations in diagnostics and the country’s national focus on personalized care, there is a need for molecular information services that enable oncologists to efficiently match patients to cancer therapies based on the molecular blueprint of each individual’s tumor.
“Healthcare is transforming at a rapid pace in
DIAN is one of the leading independent medical laboratories in
“DIAN’s sequencing expertise and its broad healthcare network will enable CGP as a critical component of patient clinical care in China,” stated Melanie Nallicheri, chief business officer and head, biopharma for
About
About DIAN
DIAN is committed to providing a “Total Solution of Medical Diagnosis Service” for its customers, with the business segment covering medical diagnosis services, IVD products, cold-chain logistics, forensic expertise, CRO business and other medical diagnostic related fields. With the mission of “Equal Access to Healthcare”, DIAN is committed to create a health industrial eco system and achieve multiple-wins for medical institutions, government and people.
Cautionary Note Regarding Forward-Looking Statements for
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding a collaboration among
1 W. Chen et al., CA Cancer J. Clin. 66, 115–132 (2016).
View source version on businesswire.com: https://www.businesswire.com/news/home/20180426006529/en/
Source:
For Foundation Medicine
Media:
Lee-Ann Murphy, 617-245-3077
pr@foundationmedicine.com
or
Investors:
Kimberly Brown, 617-418-2215
ir@foundationmedicine.com